Zahi Mitri, MD, MS

Practical considerations for the sequencing or combination of novel antibody drug conjugates to optimize outcomes for patients with HER2-low breast cancer.

Experts take a look at clinical data behind novel antibody drug conjugates and consider how they may impact the management of HER2-low breast cancer.

Focused discussion on the methods used to identify a patient’s HER2 status and why it is important to investigate in patients with breast cancer.

Shared insight on the current state of HER2 classification and testing and in breast cancer, with respect to how it may influence future treatment approaches.

Zahi Mitri, MD, MS, discusses developments in the treatment of patients with HER2-positive breast cancer.

Zahi Mitri, MD, MS, assistant professor of medicine, Oregon Health and Science University, discusses the treatment landscape of HER2-positive breast cancer.

Zahi Mitri, MD, MS, assistant professor of medicine, Oregon Health and Science University, discusses the use of neratinib (Nerlynx) and pertuzumab (Perjeta) in patients with HER2-amplified breast cancer.